Literature DB >> 27143607

Upregulation of endothelial nitric oxide synthase (eNOS) and its upstream regulators in Opisthorchis viverrini associated cholangiocarcinoma and its clinical significance.

Manida Suksawat1, Anchalee Techasen2, Nisana Namwat3, Puangrat Yongvanit3, Narong Khuntikeo4, Attapon Titapun4, Supinda Koonmee5, Watcharin Loilome6.   

Abstract

Endothelial nitric oxide synthase (eNOS) is an isoform of the enzyme nitric oxide synthase (NOS) which is constitutively expressed in endothelial cells and plays important roles in vasodilation. We previously reported the importance of eNOS activation in cholangiocarcinoma (CCA) tissues and cell lines. The present study aims to investigate the relative abundance of eNOS and phosphorylated eNOS (P-eNOS) and their upstream regulators VEGFR3, VEGFC, EphA3 and ephrin-A1, in the Opisthorchis viverrini (Ov)/N-nitrosodimethylamine (NDMA)-induced hamster CCA model and in human CCA by semiquantitative immunohistochemical analysis of the relevant tissues. Results from the hamster model suggested an increase in eNOS and P-eNOS and upstream regulators during CCA genesis. In human CCA, high immunohistochemical staining intensity of all investigated proteins was associated with the presence of metastasis. A pairwise analysis of the staining data for eNOS and its upstream regulators showed that a concurrent increase in eNOS/VEGFR3, eNOS/ephrin-A1, eNOS/VEGFC and eNOS/EphA3 was significantly associated with metastasis. An increase in eNOS/VEGFR3, eNOS/ephrin-A1 was also associated with non-papillary type CCA. Additionally, an increase in eNOS and P-eNOS was significantly correlated with a high micro-vessel level (P=0.04). Our results indicate that the development of CCA involves upregulation of eNOS and P-eNOS and their regulators. This may drive angiogenesis and metastasis in CCA.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Opisthorchis viverrini (Ov); eNOS

Mesh:

Substances:

Year:  2016        PMID: 27143607     DOI: 10.1016/j.parint.2016.04.008

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  6 in total

1.  Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan.

Authors:  Chun-Yao Huang; Ming-Ju Hsieh; Wen-Jun Wu; Whei-Ling Chiang; Tu-Chen Liu; Shun-Fa Yang; Thomas Chang-Yao Tsao
Journal:  J Cancer       Date:  2018-06-15       Impact factor: 4.207

2.  Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.

Authors:  Manida Suksawat; Jutarop Phetcharaburanin; Poramate Klanrit; Nisana Namwat; Narong Khuntikeo; Attapon Titapun; Apiwat Jarearnrat; Vanlakhone Vilayhong; Prakasit Sa-Ngiamwibool; Anchalee Techasen; Arporn Wangwiwatsin; Panupong Mahalapbutr; Jia V Li; Watcharin Loilome
Journal:  Front Public Health       Date:  2022-02-10

Review 3.  Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.

Authors:  Man Li; Xueli Zhou; Wei Wang; Baoan Ji; Yu Shao; Qianyu Du; Jinghao Yao; Yan Yang
Journal:  J Clin Transl Hepatol       Date:  2022-02-11

Review 4.  Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Authors:  Hengsong Cao; Tian Huang; Mingrui Dai; Xiangyi Kong; Hanyuan Liu; Zhiying Zheng; Guoqiang Sun; Guangshun Sun; Dawei Rong; Zehua Jin; Weiwei Tang; Yongxiang Xia
Journal:  Int J Biol Sci       Date:  2022-08-21       Impact factor: 10.750

5.  Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.

Authors:  Manida Suksawat; Anchalee Techasen; Nisana Namwat; Thianrut Boonsong; Attapol Titapun; Piti Ungarreevittaya; Puangrat Yongvanit; Watcharin Loilome
Journal:  FEBS Open Bio       Date:  2018-03-02       Impact factor: 2.693

6.  In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues.

Authors:  Manida Suksawat; Poramate Klanrit; Jutarop Phetcharaburanin; Nisana Namwat; Narong Khuntikeo; Attapol Titapun; Apiwat Jarearnrat; Prakasit Sa-Ngiamwibool; Anchalee Techasen; Watcharin Loilome
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.